canertinib dihydrochloride has been researched along with carbamates in 22 studies
*Carbamates: Derivatives of carbamic acid, H2NC(=O)OH. Included under this heading are N-substituted and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes, and polymers that include repeating units of carbamate are referred to as POLYURETHANES. Note however that polyurethanes are derived from the polymerization of ISOCYANATES and the singular term URETHANE refers to the ethyl ester of carbamic acid. [MeSH]
*Carbamates: Derivatives of carbamic acid, H2NC(=O)OH. Included under this heading are N-substituted and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes, and polymers that include repeating units of carbamate are referred to as POLYURETHANES. Note however that polyurethanes are derived from the polymerization of ISOCYANATES and the singular term URETHANE refers to the ethyl ester of carbamic acid. [MeSH]
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (carbamates) | Trials (carbamates) | Recent Studies (post-2010) (carbamates) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 13,717 | 985 | 4,744 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (77.27) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Courtney, CL; Dominick, MA; Kim, SN; Walsh, KM; Watkins, JR | 1 |
| Chevalier, P; Kuznetsov, V; Robinson, RB; Rosen, MR | 1 |
| Brodfuehrer, JI; Bullen, WW; Walter, GA; Whitfield, LR | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 2 |
| Barasoain, I; Briand, C; de Ines, C; Garcia, P; Leynadier, D; Peyrot, V; Rener, GA; Temple, C | 1 |
| MacDonald, JR; Pegg, DG | 1 |
| Delpón, E; Pérez, O; Tamargo, J; Valenzuela, C | 1 |
| Hook, KE; Leopold, WR; Przybranowski, SA | 1 |
| Cheson, BD; Ho, PT; Phillips, PH; Wright, J | 1 |
| Markoglou, N; Wainer, IW | 1 |
| Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH | 1 |
| Abbruzzese, JL; Ajani, J; Diaz-Canton, E; Grove, W; Meyers, C; Patt, Y; Pazdur, R | 1 |
| Conrad, CA; Edwards, CL; Forman, A; Freedman, RS; Grothey, A; Grove, W; Hasenburg, A; Kavanagh, JJ; Kudelka, AP; Meyers, CA; Varma, D; Verschraegen, CF | 1 |
| Benjamin, RS; Burgess, MA; Gray, R; Jenkins, J; Papadopolous, NE; Patel, SR; Plager, C; Sidhu, G | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Conrad, CA; Gelke, CK; Grove, W; Kudelka, AP; Meyers, CA; Pazdur, R | 1 |
| Vandré, DD; Weitzel, DH | 1 |
| Ansari, RH; Kugler, JW; Richards, JM; Ryan, CW; Shulman, KL; Sosman, JA; Vogelzang, NJ; Vokes, EE | 1 |
| Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP | 1 |
| Balcerzak, SP; Galloway, S; Kraut, EH; Moore, T; Thomas, JP; Vandre, DD | 1 |
| Fine, H; Hess, K; Jaeckle, K; Kunschner, LJ; Kyritsis, AP; Yung, WK | 1 |
11 trial(s) available for canertinib dihydrochloride and carbamates
| Article | Year |
|---|---|
Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase.
Topics: Antineoplastic Agents; Carbamates; Child; Chromatography, Liquid; Humans; Neoplasms; Pyrazines; Pyridines; Sensitivity and Specificity; Stereoisomerism | 1997 |
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central Nervous System Diseases; Drug Tolerance; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Pyridines | 1997 |
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyrazines; Pyridines | 1997 |
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Carbamates; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Humans; Hyponatremia; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Phlebitis; Pyrazines; Pyridines; Survival Rate; Treatment Outcome | 1998 |
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carbamates; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pyrazines; Pyridines; Sarcoma; Treatment Outcome | 1998 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia | 1997 |
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Cognition; Cognition Disorders; Colorectal Neoplasms; Female; Humans; Male; Memory; Memory Disorders; Middle Aged; Neuropsychological Tests; Neurotoxins; Ovarian Neoplasms; Pyrazines; Pyridines | 1997 |
CI-980 in advanced melanoma and hormone refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbamates; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Prostatic Neoplasms; Pyrazines; Pyridines | 2000 |
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Pyrazines; Pyridines; Skin Neoplasms; Survival Rate; Treatment Outcome | 2001 |
A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Carcinoma, Small Cell; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pyrazines; Pyridines | 2002 |
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome | 2002 |
11 other study(ies) available for canertinib dihydrochloride and carbamates
| Article | Year |
|---|---|
Proliferative bone lesions in rats given anticancer compounds.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Development; Bone Diseases; Bone Marrow; Carbamates; Cell Division; Drug Combinations; Female; Glucuronates; Injections, Intravenous; Male; Pentostatin; Pyrazines; Pyridines; Rats; Rats, Inbred Strains; Trimetrexate | 1991 |
Tubulin binding agent CI-980 has positive inotropic and local anesthetic actions.
Topics: Action Potentials; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Calcium; Carbamates; Cardiotonic Agents; Cells, Cultured; Dogs; Electrophysiology; Heart; In Vitro Techniques; Microelectrodes; Models, Biological; Myocardial Contraction; Myocardium; Purkinje Fibers; Pyrazines; Pyridines; Rats; Tubulin | 1994 |
High-performance liquid chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine.
Topics: Antineoplastic Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Freezing; Humans; Pyrazines; Pyridines; Reproducibility of Results; Spectrometry, Fluorescence | 1995 |
Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cell Division; Colchicine; Demecolcine; Docetaxel; Humans; KB Cells; Microscopy, Fluorescence; Microscopy, Immunoelectron; Microtubule Proteins; Microtubules; Paclitaxel; Pyrazines; Pyridines; Taxoids; Tubulin | 1995 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
Topics: Animals; Antineoplastic Agents; Carbamates; Cell Cycle; Cell Line; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Mice; Microtubule Proteins; Microtubules; Pyrazines; Pyridines; Tumor Cells, Cultured | 1994 |
Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Carbamates; Depression, Chemical; Extravasation of Diagnostic and Therapeutic Materials; Injections, Intradermal; Irritants; Male; Mice; Mice, Inbred BALB C; Mitosis; Pyrazines; Pyridines; Skin Ulcer; Vinblastine | 1993 |
Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Carbamates; Female; Guinea Pigs; In Vitro Techniques; Male; Papillary Muscles; Pyrazines; Pyridines; Sodium Channel Blockers | 1997 |
Cellular transport of CI-980.
Topics: Animals; Antineoplastic Agents; Biological Transport; Carbamates; Carrier Proteins; Cattle; CHO Cells; Cricetinae; Dipyridamole; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Leukemia L1210; Platelet Aggregation Inhibitors; Pyrazines; Pyridines; Stereoisomerism | 1996 |
Clinical Trials. Referral resource Clinical trials using CI-980 (mivobulin isethionate).
Topics: Antineoplastic Agents; Carbamates; Clinical Trials as Topic; Humans; Pyrazines; Pyridines | 1997 |
Differential spindle assembly checkpoint response in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Carbamates; Fluorescent Antibody Technique, Indirect; Giant Cells; Humans; Lung Neoplasms; Microtubules; Mitosis; Pyrazines; Pyridines; Spindle Apparatus; Tumor Cells, Cultured | 2000 |